TV Personality Einat Erlich Diagnosed With Aggressive Brain Cancer
Translated & summarized from Walla by baba
Israeli TV personality Einat Erlich announced her diagnosis with glioblastoma, an aggressive brain cancer. She has undergone successful surgery and is beginning further treatment, expressing determination to overcome the illness. The article also details the medical aspects of glioblastoma treatment and prognosis.
The story in 5 lines · by baba
- Einat Erlich diagnosed with aggressive glioblastoma brain cancer.
- She underwent successful surgery and is starting further treatment.
- Erlich expressed determination to recover and 'win' against the disease.
- Glioblastoma is a complex, malignant brain tumor requiring radiation and chemotherapy.
- Prognosis varies greatly depending on individual patient factors.
Israeli television personality Einat Erlich revealed on social media that she has been diagnosed with glioblastoma, an aggressive and malignant brain tumor. Erlich shared that she underwent a complex surgery last week, which she described as successful, and is now preparing to begin further treatment. She expressed her belief in healthy living but acknowledged her body's current state, stating, "My body informed me otherwise, that I am no longer healthy."
In her personal post, Erlich detailed her diagnosis with GBM, a term she never imagined writing about herself, and how it has altered her perspective on life. Despite feelings of fear, anger, and sadness, she emphasized the strong support system of her daughters, partner, family, and friends. "Thank God, I am now beginning a journey to healing," she wrote, projecting confidence: "I am strong. I am well. I am on my feet. And I will win. There is no other option."
Glioblastoma treatment typically begins with surgery to remove as much of the tumor as possible without damaging critical brain functions. The removed tissue undergoes pathological and molecular testing to determine the tumor type and inform treatment strategies, such as the potential effectiveness of chemotherapy based on MGMT methylation markers. The standard treatment protocol involves radiation therapy combined with daily oral chemotherapy, temozolomide, for about six weeks, followed by monthly chemotherapy cycles.
Some patients may also be candidates for Tumor Treating Fields (TTFields) therapy, a wearable device that uses low-intensity electrical fields to disrupt tumor cell division. Glioblastoma is known for its complexity and tendency to recur, with options for recurrent cases including further surgery, radiation, or specific medications like bevacizumab or lomustine, and clinical trials. Dr. Ido Feldor, head of the Brain Tumor Unit at Shaare Zedek Medical Center, explained that while complete tumor removal can prolong life, glioblastoma is not curable. The prognosis varies significantly based on factors like age, functional status, tumor location, extent of surgical removal, and molecular characteristics, making individual predictions difficult.
